Sutetinib (maleate)
Sutetinib maleate is the maleate form of Sutetinib. Sutetinib maleate is an orally active inhibitor for tyrosine kinase, that is associated with tumor growth and angiogenesis, such as VEGFR (Ki= 0.009 µM for VEGFR-1/2/3), PDGFR (Ki= 0.008 µM for PDGFR-α/β) and proto-oncogene cKIT. Sutetinib maleate inhibits the proliferation, migration, and tubular structure formation of endothelial cells and fibroblasts, and exhibits board-spectrum antitumor efficacy in vitro and in vivo[1].
Product Specifications
CAS Number
1701408-75-4
UNSPSC
12352005
Target
EGFR; PDGFR; VEGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sutetinib-maleate.html
Smiles
OC(/C=C\C(O)=O)=O.CCOC(C(NC(/C=C/CN(C)C)=O)=C1)=CC2=C1C(NC3=CC(C#C)=CC=C3)=C(C#N)C=N2
Molecular Formula
C30H29N5O6
Molecular Weight
555.58
References & Citations
[1]Hao Z, et al., Sunitinib: the antiangiogenic effects and beyond. Onco Targets Ther. 2016 Sep 8;9:5495-505.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD81 / TAPA-1 (1.3.3.22), CF740 conjugate, 0.1mg/mL
Complement C4d (C4D204), CF594 conjugate, 0.1mg/mL
